Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Breast Cancer
Clinical trial register · Spain

Breast Cancer Trials in Spain, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5882 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:19 UTC
5882
Studies in scope
all four open statuses
3093
Recruiting now
open to new participants
1126
Lead sponsors
across recruiting studies
Top sites
Barcelona 74 Madrid 68 Seville 26 Valencia 25 L'Hospitalet de Llobregat 22
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca13 Hoffmann-La Roche9 Pfizer7 Eli Lilly and Company6 MedSIR5 Hospital Universitari de Bellvitge5 Novartis Pharmaceuticals4 SOLTI Breast Cancer Research Group3 Genentech, Inc.3 Daiichi Sankyo2 Stemline Therapeutics, Inc.2 Relay Therapeutics, Inc.2 Merck Sharp & Dohme LLC2 University Hospital A Coruña2 Jazz Pharmaceuticals2 Olema Pharmaceuticals, Inc.2 Celcuity Inc2 University of Valencia2 Fundacion Miguel Servet1 Universidad Rey Juan Carlos1 Bristol-Myers Squibb1 Clinica Universidad de Navarra, Universidad de Navarra1 ARTIDIS AG1 European Organisation for Research and Treatment of Cancer - EORTC1 Kenko Imalytics S.L.1 University of Vigo1 European University Miguel de Cervantes1 Shanghai Henlius Biotech1 Alliance Foundation Trials, LLC.1 Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal1 GO fit Lab- Ingesport1 Fundación para la Investigación del Hospital Clínico de Valencia1 Hospital Costa del Sol1 University of Castilla-La Mancha1 Federal University of São Paulo1 UNICANCER1 Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental1 OnKure, Inc.1 Region Örebro County1 Terremoto Biosciences Inc.1 Umbria Bioengineering Technologies1 GBG Forschungs GmbH1 Alterome Therapeutics, Inc.1 BicycleTx Limited1 Establishment Labs1 Toralf Reimer, MD PhD1 European Breast Cancer Research Association of Surgical Trialists1 Lucía Graña López1 University of Vic - Central University of Catalonia1 Universidad de Extremadura1 Omphis Foundation1 SERGIO MONTERO NAVARRO1 BeOne Medicines1 University Hospital, Basel, Switzerland1 University of Extremadura1 Greenwich LifeSciences, Inc.1 Atavistik Bio, Inc1
Site location
Barcelona74 Madrid68 Seville26 Valencia25 L'Hospitalet de Llobregat22 Málaga20 Granada20 A Coruña19 Badalona15 Badajoz13 Cáceres12 Pamplona10 Córdoba9 Bilbao9 Santiago de Compostela8 Alicante7 Pozuelo de Alarcón7 Lleida7 Elche6 Jaén6 Vigo6 Santa Cruz de Tenerife4 León4 Donostia / San Sebastian4 Murcia4 Girona4 Jerez de la Frontera4 Castellon4 El Palmar4 Zaragoza4 Fuenlabrada4 San Cristóbal de La Laguna4 Majadahonda3 Bilbao (Vizcaya)3 Salamanca3 Santander3 Toledo3 Huelva2 Las Palmas de Gran Canaria2 Pontevedra2 Ávila2 Reus2 Oviedo2 Hospitalet deLlobregat2 Sabadell2 Palma de Mallorca2 Sant Cugat del Vallès2 Móstoles2 Manresa2 Lugo2 Hospitalet1 Valladolid1 Castelló1 Burgos1 Santiago de Compostela-Coruña1 Torrejón de Ardoz1 Alcorcón1 Pamplona/iruña1 Logroño1 Marbella1 Las Palmas1 Vilanova1 Sant Joan Despí1 Elche(Alicante)1 Vic1 Cerdanyola del Vallès1 Albacete1 Calella1 Granollers1 Mataró1 Terrassa1 Ferrol1 Ourense1
All 73 locations
Target enrolment
to

Breast Cancer trials in Spain

112 of 5882 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Not yet open
EmpowerHer: Hybrid Digital Intervention for Breast Cancer Survivors
NCT07676591Breast Cancer, Cancer Survivors, Quality of Life, Exercise Therapy
University of Valencia
Not applicable
147
Valencia
2027-07-01
Not yet open
University of Castilla-La Mancha
Not applicable
44
Toledo
2026-09
Recruiting
Kenko Imalytics S.L.
Observational
200
Elche
2026-07-22
Recruiting
European University Miguel de Cervantes
Not applicable
66
Valladolid
2026-04-14
Recruiting
University of Extremadura
Not applicable
40
Badajoz
2026-04-14
Recruiting
Luminal Breast Cancer Cryoablation
NCT07447414Breast Cancer, Breast Cancer (Early Breast Cancer)
Lucía Graña López
Not applicable
140
Lugo
2026-04-08
Recruiting
Hoffmann-La Roche
Phase 2
80
L'Hospitalet de Llobregat, Barcelona, Granada, Madrid, Valencia
2026-04-07
Not yet open
University of Vic - Central University of Catalonia
Not applicable
70
Vic
2026-04
Recruiting
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer
NCT07195227Hormon Receptor Positive Breast Cancer, Breast Cancer
DrugsCamizestrant·Ribociclib
MedSIR
Phase 2
150
Alicante, Barcelona, Girona, Granada, Jerez de la Frontera, León, Madrid, Málaga
2026-03-24
Active, closed
Hospital Universitari de Bellvitge
Not applicable
100
L'Hospitalet de Llobregat
2026-03-01
Recruiting
Hoffmann-La Roche
Phase 2
80
Barcelona, Granada, Madrid, Valencia
2026-02-18
Recruiting
UNICANCER
Phase 3
3,902
Badajoz, Barcelona, Bilbao, Fuenlabrada, Granada, Jaén, Jerez de la Frontera, L'Hospitalet de Llobregat
2025-12-18
Recruiting
BeOne Medicines
Phase 1
86
Barcelona, Madrid, Málaga
2025-12-11
Recruiting
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
NCT07085767Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Ribociclib·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
1,000
Alicante, Barcelona, Granada, León, Lleida, Madrid, Murcia, Seville
2025-11-03
Recruiting
AstraZeneca
Phase 3
100
A Coruña, Barcelona, Granada, Madrid, Seville, Valencia
2025-10-30
Recruiting
Role of Pro-Resolving Lipid Mediators in Obesity-Associated Diseases
NCT07447440Breast Cancer, Health, Subjective, Obesity
Clinica Universidad de Navarra, Universidad de Navarra
Observational
60
Pamplona
2025-10-15
Recruiting
Genentech, Inc.
Phase 1/2
285
L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia
2025-10-07
Not yet open
Hospital Costa del Sol
Not applicable
90
Marbella, Santa Cruz de Tenerife
2025-10-01
Recruiting
Jazz Pharmaceuticals
Phase 2
125
Granada, Vigo, Barcelona, Madrid, Málaga, Palma de Mallorca
2025-09-24
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
DrugFulvestrant
Terremoto Biosciences Inc.
Phase 1/2
248
Barcelona, Madrid
2025-09-23
Recruiting
Hoffmann-La Roche
Phase 2
120
Barcelona, Madrid, Salamanca, Seville, Valencia
2025-09-09
Recruiting
Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal
Not applicable
50
Madrid
2025-09-01
Not yet open
Universidad de Extremadura
Not applicable
220
Badajoz
2025-09-01
Recruiting
Relay Therapeutics, Inc.
Phase 3
540
Badajoz, Badalona, Barcelona, Castellon, Cáceres, El Palmar, Girona, Huelva
2025-08-26
Recruiting
Universidad Rey Juan Carlos
Not applicable
10
Madrid
2025-08-23
Recruiting
Pfizer
Phase 3
400
A Coruña, Barcelona, Bilbao, Málaga, Granada, Jaén, Madrid, Zaragoza
2025-08-05
Active, closed
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
DrugATV-1601
Atavistik Bio, Inc
Phase 1
134
Madrid
2025-07-29
Recruiting
Celcuity Inc
Phase 3
1,180
A Coruña, Badajoz, Barcelona, Cáceres, El Palmar, L'Hospitalet de Llobregat, Lleida, Madrid
2025-07-24
Recruiting
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
Observational
70
Granada
2025-07-15
Active, closed
Pfizer
Phase 1/2
74
Barcelona, Madrid, Valencia
2025-06-30
Recruiting
GO fit Lab- Ingesport
Observational
200
Madrid
2025-06-06
Not yet open
Effects of Two Strength Exercise Programs on Upper Limb Functionality in Breast Cancer
NCT06952270Breast Cancer Survivor, Breast Cancer, Breast Cancer Patients, Breast Cancer - Female
University of Vigo
Not applicable
24
Pontevedra
2025-05-02
Recruiting
Hoffmann-La Roche
Phase 3
450
Elche, L'Hospitalet de Llobregat, Pamplona/iruña, Bilbao, Barcelona, Madrid, Málaga, Seville
2025-04-09
Recruiting
Merck Sharp & Dohme LLC
Phase 2
372
Badalona, Madrid, Córdoba
2025-03-20
Active, closed
BicycleTx Limited
Phase 2
66
Barcelona, Madrid
2025-03-03
Recruiting
Bristol-Myers Squibb
Phase 1/2
416
Santiago de Compostela, Barcelona, Hospitalet, Madrid, Majadahonda, Valencia, Málaga, Seville
2025-02-04
Recruiting
Radiofrequency and Exercise-based Rehabilitation on Symptoms Associated With Pelvic Floor Dysfunctions in Breast Cancer
NCT06694519Breast Cancer, Genitourinary Syndrome, Radiofrequency, Physical Exercise
SERGIO MONTERO NAVARRO
Not applicable
117
Elche
2025-01-30
Recruiting
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
NCT06695845Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer
DrugZanidatamab
Jazz Pharmaceuticals
Phase 2
200
Las Palmas, Pamplona, Barcelona, Madrid, Málaga, Valencia
2025-01-14
Active, closed
Pfizer
Phase 3
1,035
A Coruña, Elche, Seville, Barcelona, L'Hospitalet de Llobregat, Bilbao, Jerez de la Frontera, Madrid
2025-01-06
Recruiting
Multicomponent Prehabilitation in Older Adults With Breast Cancer
NCT07531836Breast Cancer, Frailty, Sarcopenia, Aging
Fundacion Miguel Servet
Not applicable
90
Pamplona
2024-12-04
Active, closed
Stemline Therapeutics, Inc.
Phase 3
4,556
Vigo, Seville, Badalona, Sant Cugat del Vallès, Sant Joan Despí, San Cristóbal de La Laguna, Cáceres, Móstoles
2024-09-27
By invitation
University of Valencia
Observational
111
Valencia
2024-09-01
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
Barcelona, Madrid
2024-08-22
Active, closed
Novartis Pharmaceuticals
Phase 1/2
20
L'Hospitalet de Llobregat, Barcelona, Madrid
2024-08-14
By invitation
Federal University of São Paulo
Observational
4,500
Madrid
2024-08-01
Active, closed
MedSIR
Phase 2
28
Alicante, Barcelona, Bilbao, Córdoba, Granada, Madrid, Seville, Valencia
2024-06-05
Active, closed
The OPBC-07/microNAC Study
NCT06529302Breast Cancer
University Hospital, Basel, Switzerland
Observational
2,000
Barcelona, Madrid
2024-05-15
Recruiting
Hoffmann-La Roche
Phase 4
320
Madrid, Seville, Valencia
2024-04-02
Active, closed
MedSIR
Phase 2
976
A Coruña, Alicante, Barcelona, Bilbao, Castellon, Córdoba, Elche, Girona
2024-04-01
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
DrugsAtirmociclib·Tucatinib·Ribociclib·Fulvestrant
OnKure, Inc.
Phase 1
200
Barcelona, Madrid
2024-02-26
Active, closed
Pfizer
Phase 1/2
71
Barcelona, Lleida, Madrid, Seville
2024-02-19
Recruiting
Evaluation of Improvements in Patient-reported Quality of Life
NCT06002022Breast Cancer, Quality of Life, Physical Activity, Sleep Quality
Fundación para la Investigación del Hospital Clínico de Valencia
Not applicable
110
Valencia
2024-01-01
Recruiting
Omphis Foundation
Observational
15,000
Cerdanyola del Vallès
2024-01-01
Recruiting
Daiichi Sankyo
Phase 3
250
Barcelona, Donostia / San Sebastian, Granada, Las Palmas de Gran Canaria, Madrid, Majadahonda, Murcia, Pamplona
2023-12-30
Recruiting
AstraZeneca
Phase 3
625
Barcelona, Granada, Hospitalet deLlobregat, Madrid, Pamplona, Santander
2023-11-23
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Badajoz, Badalona, Manresa, Girona, León, Lleida, Madrid, Pamplona
2023-11-16
Active, closed
AstraZeneca
Phase 3
1,902
Barcelona, Granada, Hospitalet deLlobregat, Madrid, Santiago de Compostela, Seville, Zaragoza
2023-11-14
Active, closed
Novartis Pharmaceuticals
Phase 1
28
L'Hospitalet de Llobregat, Barcelona, Madrid
2023-11-13
Recruiting
ARTIDIS AG
Not applicable
2,706
Barcelona
2023-11-02
Recruiting
European Breast Cancer Research Association of Surgical Trialists
Observational
1,236
Barcelona
2023-09-12
Recruiting
Motiva Flora® Aesthetic Breast Recon® Clinical Study
NCT06146231Mammaplasty, Breast Cancer, Poland Syndrome
Establishment Labs
Not applicable
66
Barcelona
2023-08-18
Active, closed
Pfizer
Phase 3
59
Badalona, Barcelona, Jaén, Málaga, Granada, Madrid
2023-08-09
Recruiting
Hoffmann-La Roche
Phase 3
420
L'Hospitalet de Llobregat, Santiago de Compostela, San Cristóbal de La Laguna, Barcelona, Cáceres, Madrid, Málaga, Murcia
2023-06-07
Active, closed
PIK3CA/PTEN-altered Advanced Breast Cancer Treated With MEN1611 Monotherapy or in Combination With Eribulin
NCT05810870Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
DrugEribulin
MedSIR
Phase 2
14
Granada, Seville, Donostia / San Sebastian, Santander, A Coruña, Torrejón de Ardoz, Vigo, Barcelona
2023-05-24
Recruiting
Eli Lilly and Company
Phase 1/2
880
Barcelona, Logroño, Madrid, Pozuelo de Alarcón, Reus, Seville
2023-04-17
Active, closed
Pfizer
Phase 1/2
37
Barcelona, Madrid, Pamplona, Seville
2023-02-23
Recruiting
Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
NCT05982093Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Premenopausal Breast Cancer
DrugsElacestrant·Tamoxifen
SOLTI Breast Cancer Research Group
Phase 2
96
Badalona, L'Hospitalet de Llobregat, Vilanova, El Palmar, Badajoz, Barcelona, Cáceres, Madrid
2023-02-03
Active, closed
Stemline Therapeutics, Inc.
Phase 1/2
435
A Coruña, Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Valencia
2023-01-24
Recruiting
Umbria Bioengineering Technologies
Not applicable
600
Toledo
2023-01-07
Recruiting
Greenwich LifeSciences, Inc.
Phase 3
2,250
Albacete, Alicante, Badajoz, Barcelona, Cáceres, Córdoba, El Palmar, Fuenlabrada
2022-12-16
Active, closed
Celcuity Inc
Phase 3
701
Madrid, Badajoz, Barcelona, Cáceres, Murcia, Santiago de Compostela
2022-12-08
Active, closed
AstraZeneca
Phase 3
1,174
Barcelona, Bilbao (Vizcaya), Elche(Alicante), Madrid, Málaga, Palma de Mallorca, Toledo, Valencia
2022-11-28
Active, closed
SOLTI Breast Cancer Research Group
Phase 2
120
Badalona, Santa Cruz de Tenerife, A Coruña, Fuenlabrada, Móstoles, Badajoz, Barcelona, Bilbao
2022-11-25
Recruiting
GBG Forschungs GmbH
Observational
400
Córdoba, Bilbao, Santa Cruz de Tenerife, Badalona, Barcelona, Lleida, Sabadell, Cáceres
2022-10-12
Active, closed
AstraZeneca
Phase 3
644
Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Santiago de Compostela, Seville
2022-05-16
Active, closed
Eli Lilly and Company
Phase 1
260
Barcelona, Madrid, Pozuelo de Alarcón, Valencia
2022-05-11
Active, closed
Shanghai Henlius Biotech
Phase 3
900
Santiago de Compostela, Barcelona
2022-04-25
Active, closed
Pfizer
Phase 1/2
235
Barcelona, Madrid, Seville
2022-03-14
Active, closed
Novartis Pharmaceuticals
Phase 3
210
Badajoz, Pozuelo de Alarcón, Oviedo, A Coruña, Barcelona, Madrid, Málaga, Zaragoza
2021-12-17
Recruiting
Relay Therapeutics, Inc.
Phase 1
930
Barcelona, Valencia, Madrid
2021-12-08
Active, closed
AstraZeneca
Phase 3
927
Barcelona, Madrid, Seville, Vigo
2021-10-25
Active, closed
AstraZeneca
Phase 3
732
A Coruña, Barcelona, Bilbao (Vizcaya), Huelva, L'Hospitalet de Llobregat, Madrid, Málaga, Seville
2021-10-18
Recruiting
AstraZeneca
Phase 1/2
460
Barcelona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona
2021-10-18
Active, closed
AstraZeneca
Phase 3
506
Barcelona, Bilbao (Vizcaya), Granada, Madrid, Salamanca, Santander, Santiago de Compostela-Coruña, Seville
2021-06-22
Recruiting
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
NCT04889924Breast Cancer, Chemotherapy, Sentinel Lymph Node, Axillary Lymph Nodes Dissection
Hospital Universitari de Bellvitge
Not applicable
820
Badalona, Calella, Granollers, L'Hospitalet de Llobregat, Manresa, Mataró, Sant Cugat del Vallès, Terrassa
2021-06-11
Active, closed
Hoffmann-La Roche
Phase 3
1,188
Elche, Badalona, Sabadell, Jerez de la Frontera, Vigo, San Cristóbal de La Laguna, Bilbao, Granada
2021-05-04
Active, closed
University Hospital A Coruña
Observational
82
Ferrol, Santiago de Compostela, Vigo, A Coruña, Lugo, Ourense, Pontevedra
2021-04-20
Active, closed
SOLTI Breast Cancer Research Group
Phase 2
55
Granada, Barcelona, L'Hospitalet de Llobregat, Santa Cruz de Tenerife, A Coruña, Alicante, Cáceres, León
2021-03-15
Active, closed
Artificial Intelligence Supporting CAncer Patients Across Europe - the ASCAPE Project
NCT04879563Breast Cancer, Prostate Cancer, Quality of Life, Survivorship
Region Örebro County
Phase 2
500
Barcelona
2021-02-01
Recruiting
TAD After Chemotherapy in Locally Advanced Breast Cancer
NCT05763641Sentinel Lymph Node, Breast Cancer, Locally Advanced
Hospital Universitari de Bellvitge
Observational
162
L'Hospitalet de Llobregat, Barcelona
2021-02-01
Active, closed
Toralf Reimer, MD PhD
Not applicable
350
Madrid
2021-01-13
Recruiting
Hospital Universitari de Bellvitge
Observational
43
L'Hospitalet de Llobregat
2021-01-01
Active, closed
AstraZeneca
Phase 1/2
702
Barcelona, Madrid, Málaga, Pozuelo de Alarcón, Seville
2020-11-12
Recruiting
Impact of Systematic Shaving on Margins
NCT05782686Margin, Tumor-Free, Breast Cancer, Surgery
Hospital Universitari de Bellvitge
Not applicable
234
L'Hospitalet de Llobregat
2020-10-07
Active, closed
AstraZeneca
Phase 3
185
Badalona, Barcelona, Córdoba, Donostia / San Sebastian, Granada, Madrid, Pamplona, Valencia
2020-08-04
Active, closed
The PreQ-20 TRIAL, a Prospective Cohort Study of Patients Undergoing Prepectoral Breast Reconstruction
NCT04642508Breast Cancer, Quality of Life, Surgery--Complications
University Hospital A Coruña
Not applicable
81
A Coruña
2020-06-22
Active, closed
Daiichi Sankyo
Phase 1
115
A Coruña, Barcelona, Las Palmas de Gran Canaria, Madrid, Seville, Zaragoza
2020-02-10
Active, closed
Hoffmann-La Roche
Phase 2/3
325
Badalona, Pamplona, San Cristóbal de La Laguna, Barcelona, Jaén, Madrid, Seville, Valencia
2020-01-29
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Barcelona, Madrid, Valencia
2019-12-10
Active, closed
Merck Sharp & Dohme LLC
Phase 3
1,240
L'Hospitalet de Llobregat, A Coruña, Pozuelo de Alarcón, Madrid, Valencia, Barcelona, Jaén, Seville
2018-12-27
Active, closed
Genentech, Inc.
Phase 1
181
L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia
2017-11-24
Active, closed
Eli Lilly and Company
Phase 3
5,637
Córdoba, Barcelona, Santiago de Compostela, Lleida, Pozuelo de Alarcón, Alcorcón, Madrid, Málaga
2017-07-12
Active, closed
MedSIR
Phase 2
377
Badalona, L'Hospitalet de Llobregat, Castelló, Jaén, Málaga, Reus, A Coruña, Barcelona
2017-06-26
Active, closed
Genentech, Inc.
Phase 1
200
Barcelona, Valencia
2016-12-13
Active, closed
Eli Lilly and Company
Phase 1
100
Ávila, Cáceres, Madrid
2016-11-14
Active, closed
Hoffmann-La Roche
Phase 2
534
Fuenlabrada, Barcelona, Madrid, Málaga, Seville
2015-11-19
Active, closed
Alliance Foundation Trials, LLC.
Phase 3
5,796
A Coruña, Alicante, Badalona, Barcelona, Burgos, Castellon, Cáceres, Córdoba
2015-08
Active, closed
Eli Lilly and Company
Phase 3
493
Badajoz, Barcelona, Donostia / San Sebastian, Lleida, Madrid, Valencia
2014-11-06
Active, closed
AstraZeneca
Phase 3
1,837
A Coruña, Ávila, Badajoz, Badalona, Barcelona, Castellon, Cáceres, Córdoba
2014-04-22
Active, closed
Novartis Pharmaceuticals
Phase 1/2
259
Madrid, Seville, Valencia
2013-10-22
Active, closed
European Organisation for Research and Treatment of Cancer - EORTC
Observational
200
Barcelona, Madrid
2010-12
Active, closed
AstraZeneca
Phase 3
736
A Coruña, Madrid, Málaga, Oviedo, Salamanca, Seville
2005-02-13
Rows per page Showing 1–112 of 112
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 12 November 2026. https://priyalifescience.com/clinical-trials-spain/condition/breast-cancer

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,882 studies in total at the last sync on 10 Nov 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 112 of those studies listing the condition Breast Cancer.

How many Breast Cancer trials are recruiting in Spain?

49 of the 112 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:19 UTC sync. A further 6 have not yet opened recruitment, 55 are active but closed to new participants, and 2 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Breast Cancer), 112 studies
PhaseStudiesRecruitingShare
Phase 3321128.6%
Not applicable221319.6%
Phase 217815.2%
Observational14912.5%
Phase 1/213511.6%
Phase 112210.7%
Phase 2/3100.9%
Phase 4110.9%

Most active sponsors

Lead sponsors with the most studies (Breast Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca133
Hoffmann-La Roche96
Pfizer71
Eli Lilly and Company61
Hospital Universitari de Bellvitge54
MedSIR51
Novartis Pharmaceuticals40
Genentech, Inc.31
SOLTI Breast Cancer Research Group31
Celcuity Inc21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.